{
    "id": "correct_subsidiary_00047_3",
    "rank": 98,
    "data": {
        "url": "https://patents.google.com/patent/US7141237B2/en11",
        "read_more_link": "",
        "language": "en",
        "title": "US7141237B2 - Pharmaceutical foam - Google Patents",
        "top_image": "",
        "meta_img": "",
        "images": [
            "https://patentimages.storage.googleapis.com/b8/8a/dd/dfff987c678b4a/US07141237-20061128-D00001.png",
            "https://patentimages.storage.googleapis.com/16/74/f2/61f18df544a8df/US07141237-20061128-D00002.png",
            "https://patentimages.storage.googleapis.com/a2/4f/8a/d76a5026dbc64b/US07141237-20061128-D00003.png",
            "https://patentimages.storage.googleapis.com/f0/4f/77/d64718d4ad8c6e/US07141237-20061128-D00004.png",
            "https://patentimages.storage.googleapis.com/44/ca/19/cc7ac5ea39ae53/US07141237-20061128-D00005.png",
            "https://patentimages.storage.googleapis.com/b6/51/87/a9bf1e4a0f168d/US07141237-20061128-D00006.png",
            "https://patentimages.storage.googleapis.com/bf/06/1d/2d0b8f4b89575b/US07141237-20061128-D00007.png",
            "https://patentimages.storage.googleapis.com/8f/a2/6f/d08575d3784cd1/US07141237-20061128-D00008.png",
            "https://patentimages.storage.googleapis.com/82/61/3b/02ea2bc70fa398/US07141237-20061128-D00009.png"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": "2003-01-24T00:00:00",
        "summary": "",
        "meta_description": "",
        "meta_lang": "en",
        "meta_favicon": "",
        "meta_site_name": "",
        "canonical_link": "https://patents.google.com/patent/US7141237B2/en11",
        "text": "Pharmaceutical foam Download PDF\n\nInfo\n\nPublication number\n\nUS7141237B2\n\nUS7141237B2 US10/763,379 US76337904A US7141237B2 US 7141237 B2 US7141237 B2 US 7141237B2 US 76337904 A US76337904 A US 76337904A US 7141237 B2 US7141237 B2 US 7141237B2\n\nAuthority\n\nUS\n\nUnited States\n\nPrior art keywords\n\ncomposition\n\nalcohol\n\nfoam\n\nquick\n\nclindamycin\n\nPrior art date\n\n2003-01-24\n\nLegal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)\n\nExpired - Lifetime, expires 2024-02-03\n\nApplication number\n\nUS10/763,379\n\nOther languages\n\nEnglish (en)\n\nOther versions\n\nUS20040151671A1 (en\n\nInventor\n\nAlbert Zorko Abram\n\nBarry Thomas Hunt\n\nCurrent Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)\n\nStiefel West Coast LLC\n\nOriginal Assignee\n\nConnetics Australia Pty Ltd\n\nPriority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)\n\n2003-01-24\n\nFiling date\n\n2004-01-23\n\nPublication date\n\n2006-11-28\n\nFamily has litigation\n\nFirst worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32776128&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US7141237(B2) \"Global patent litigation datasetâ by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.\n\nUS case filed in Delaware District Court litigation https://portal.unifiedpatents.com/litigation/Delaware%20District%20Court/case/1%3A09-cv-00167 Source: District Court Jurisdiction: Delaware District Court \"Unified Patents Litigation Data\" by Unified Patents is licensed under a Creative Commons Attribution 4.0 International License.\n\nUS case filed in Delaware District Court litigation https://portal.unifiedpatents.com/litigation/Delaware%20District%20Court/case/1%3A17-cv-00970 Source: District Court Jurisdiction: Delaware District Court \"Unified Patents Litigation Data\" by Unified Patents is licensed under a Creative Commons Attribution 4.0 International License.\n\nUS case filed in New York Southern District Court litigation https://portal.unifiedpatents.com/litigation/New%20York%20Southern%20District%20Court/case/1%3A17-cv-05405 Source: District Court Jurisdiction: New York Southern District Court \"Unified Patents Litigation Data\" by Unified Patents is licensed under a Creative Commons Attribution 4.0 International License.\n\nUS case filed in Delaware District Court litigation https://portal.unifiedpatents.com/litigation/Delaware%20District%20Court/case/1%3A17-cv-01653 Source: District Court Jurisdiction: Delaware District Court \"Unified Patents Litigation Data\" by Unified Patents is licensed under a Creative Commons Attribution 4.0 International License.\n\n2004-01-23 Priority to US10/763,379 priority Critical patent/US7141237B2/en\n\n2004-01-23 Application filed by Connetics Australia Pty Ltd filed Critical Connetics Australia Pty Ltd\n\n2004-08-05 Publication of US20040151671A1 publication Critical patent/US20040151671A1/en\n\n2006-02-07 Priority to US11/349,820 priority patent/US7749488B2/en\n\n2006-08-09 Priority to US11/463,573 priority patent/US7374747B2/en\n\n2006-11-28 Publication of US7141237B2 publication Critical patent/US7141237B2/en\n\n2006-11-28 Application granted granted Critical\n\n2007-06-19 Assigned to STIEFEL RESEARCH AUSTRALIA PTY LTD reassignment STIEFEL RESEARCH AUSTRALIA PTY LTD CHANGE OF NAME Assignors: CONNETICS AUSTRALIA PTY LTD\n\n2010-05-20 Priority to US12/783,824 priority patent/US20100266511A1/en\n\n2011-11-30 Priority to US13/307,533 priority patent/US8586008B2/en\n\n2013-05-08 Assigned to CONNETICS CORPORATION, STIEFEL LABORATORIES, INC. reassignment CONNETICS CORPORATION RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: DEUTSCHE BANK TRUST COMPANY AMERICAS\n\n2013-05-08 Assigned to STIEFEL LABORATORIES, INC., CONNETICS CORPORATION reassignment STIEFEL LABORATORIES, INC. RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: DEUTSCHE BANK TRUST COMPANY AMERICAS\n\n2013-05-30 Assigned to STIEFEL WEST COAST, LLC reassignment STIEFEL WEST COAST, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: STIEFEL RESEARCH AUSTRALIA PTY LTD\n\n2013-10-14 Priority to US14/053,085 priority patent/US9486394B2/en\n\n2024-02-03 Adjusted expiration legal-status Critical\n\nStatus Expired - Lifetime legal-status Critical Current\n\nLinks\n\nUSPTO\n\nUSPTO PatentCenter\n\nUSPTO Assignment\n\nEspacenet\n\nGlobal Dossier\n\nDiscuss\n\n239000008255 pharmaceutical foam Substances 0.000 title 1\n\n239000006260 foam Substances 0.000 claims abstract description 284\n\n239000000203 mixture Substances 0.000 claims abstract description 243\n\n239000004088 foaming agent Substances 0.000 claims abstract description 48\n\n238000011282 treatment Methods 0.000 claims abstract description 48\n\n230000000699 topical effect Effects 0.000 claims abstract description 22\n\n230000001476 alcoholic effect Effects 0.000 claims abstract description 9\n\n201000010099 disease Diseases 0.000 claims abstract description 6\n\n208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 6\n\nUFUVLHLTWXBHGZ-MGZQPHGTSA-N [(2r,3r,4s,5r,6r)-6-[(1s,2s)-2-chloro-1-[[(2s,4r)-1-methyl-4-propylpyrrolidine-2-carbonyl]amino]propyl]-4,5-dihydroxy-2-methylsulfanyloxan-3-yl] dihydrogen phosphate Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@@H](SC)O1 UFUVLHLTWXBHGZ-MGZQPHGTSA-N 0.000 claims description 114\n\n229960002291 clindamycin phosphate Drugs 0.000 claims description 102\n\nLFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 93\n\nXLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 69\n\n239000003380 propellant Substances 0.000 claims description 53\n\nGLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 44\n\nBXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 43\n\nDNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 30\n\nKWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical group [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 29\n\n206010000496 acne Diseases 0.000 claims description 25\n\n239000002585 base Substances 0.000 claims description 22\n\n229960000541 cetyl alcohol Drugs 0.000 claims description 22\n\nGOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 22\n\n208000002874 Acne Vulgaris Diseases 0.000 claims description 21\n\n229930195733 hydrocarbon Natural products 0.000 claims description 20\n\n150000002430 hydrocarbons Chemical class 0.000 claims description 20\n\n239000004215 Carbon black (E152) Substances 0.000 claims description 19\n\n239000004094 surface-active agent Substances 0.000 claims description 19\n\nLCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims description 16\n\nOKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15\n\nPEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 10\n\nKYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 claims description 8\n\n239000003974 emollient agent Substances 0.000 claims description 8\n\n241000894006 Bacteria Species 0.000 claims description 5\n\nLRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 4\n\n229920005862 polyol Polymers 0.000 claims description 4\n\n150000003077 polyols Chemical group 0.000 claims description 4\n\n230000001404 mediated effect Effects 0.000 claims description 3\n\n229920000136 polysorbate Polymers 0.000 claims description 3\n\nBVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 2\n\nBVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2\n\n229910001854 alkali hydroxide Inorganic materials 0.000 claims description 2\n\n229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 claims description 2\n\n239000012456 homogeneous solution Substances 0.000 claims description 2\n\n239000002563 ionic surfactant Substances 0.000 claims description 2\n\n229950008882 polysorbate Drugs 0.000 claims description 2\n\nBDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 2\n\n229910052723 transition metal Inorganic materials 0.000 claims description 2\n\n150000003624 transition metals Chemical class 0.000 claims description 2\n\n150000008044 alkali metal hydroxides Chemical class 0.000 claims 1\n\nXETRDYSPPPDVAB-UHFFFAOYSA-N butan-1-ol;propan-1-ol Chemical compound CCCO.CCCCO XETRDYSPPPDVAB-UHFFFAOYSA-N 0.000 claims 1\n\n239000002736 nonionic surfactant Substances 0.000 claims 1\n\n238000000034 method Methods 0.000 abstract description 39\n\n150000001875 compounds Chemical class 0.000 abstract description 36\n\n208000015181 infectious disease Diseases 0.000 abstract description 3\n\nKDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 138\n\n229960002227 clindamycin Drugs 0.000 description 127\n\n238000009472 formulation Methods 0.000 description 73\n\n210000003491 skin Anatomy 0.000 description 60\n\n239000000243 solution Substances 0.000 description 58\n\n230000003902 lesion Effects 0.000 description 30\n\n239000000443 aerosol Substances 0.000 description 27\n\n229960004756 ethanol Drugs 0.000 description 27\n\n150000003839 salts Chemical class 0.000 description 25\n\n239000000651 prodrug Substances 0.000 description 24\n\n229940002612 prodrug Drugs 0.000 description 24\n\n239000003242 anti bacterial agent Substances 0.000 description 22\n\n230000002757 inflammatory effect Effects 0.000 description 22\n\n238000010521 absorption reaction Methods 0.000 description 19\n\n239000003814 drug Substances 0.000 description 19\n\n230000000007 visual effect Effects 0.000 description 18\n\n239000013543 active substance Substances 0.000 description 17\n\n239000000872 buffer Substances 0.000 description 17\n\n229940079593 drug Drugs 0.000 description 17\n\nATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 16\n\n239000004342 Benzoyl peroxide Substances 0.000 description 15\n\nOMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 15\n\n235000019400 benzoyl peroxide Nutrition 0.000 description 15\n\n239000012071 phase Substances 0.000 description 15\n\n238000012360 testing method Methods 0.000 description 15\n\nULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 14\n\n230000009467 reduction Effects 0.000 description 14\n\n239000012530 fluid Substances 0.000 description 13\n\nWEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12\n\n229940088710 antibiotic agent Drugs 0.000 description 12\n\n229940055343 clindagel Drugs 0.000 description 12\n\n210000004207 dermis Anatomy 0.000 description 12\n\nLXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 12\n\nYGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 12\n\n230000003115 biocidal effect Effects 0.000 description 11\n\n239000000047 product Substances 0.000 description 11\n\n230000003068 static effect Effects 0.000 description 11\n\n-1 adapalene) Chemical class 0.000 description 10\n\n238000009826 distribution Methods 0.000 description 10\n\n210000002615 epidermis Anatomy 0.000 description 10\n\n239000003002 pH adjusting agent Substances 0.000 description 10\n\n150000004492 retinoid derivatives Chemical class 0.000 description 10\n\n229920001214 Polysorbate 60 Polymers 0.000 description 9\n\n230000015556 catabolic process Effects 0.000 description 9\n\n230000000694 effects Effects 0.000 description 9\n\nSFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 9\n\n239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 9\n\n235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 9\n\n229940113124 polysorbate 60 Drugs 0.000 description 9\n\n229960004063 propylene glycol Drugs 0.000 description 9\n\n239000008213 purified water Substances 0.000 description 9\n\n229920002884 Laureth 4 Polymers 0.000 description 8\n\n239000004098 Tetracycline Substances 0.000 description 8\n\n229940121375 antifungal agent Drugs 0.000 description 8\n\n239000003795 chemical substances by application Substances 0.000 description 8\n\n238000006731 degradation reaction Methods 0.000 description 8\n\n150000002191 fatty alcohols Chemical class 0.000 description 8\n\n230000004907 flux Effects 0.000 description 8\n\n230000006870 function Effects 0.000 description 8\n\n229940061515 laureth-4 Drugs 0.000 description 8\n\nIJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 8\n\n239000001294 propane Substances 0.000 description 8\n\n229960002180 tetracycline Drugs 0.000 description 8\n\n229930101283 tetracycline Natural products 0.000 description 8\n\n235000019364 tetracycline Nutrition 0.000 description 8\n\n150000003522 tetracyclines Chemical class 0.000 description 8\n\nSGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 7\n\nFFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 7\n\n206010033733 Papule Diseases 0.000 description 7\n\n230000002411 adverse Effects 0.000 description 7\n\nSHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\\C=C(/C)\\C=C\\C=C(/C)\\C=C\\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 7\n\n229910052782 aluminium Inorganic materials 0.000 description 7\n\n239000003429 antifungal agent Substances 0.000 description 7\n\n229960003722 doxycycline Drugs 0.000 description 7\n\n229960003276 erythromycin Drugs 0.000 description 7\n\n238000011049 filling Methods 0.000 description 7\n\n238000000338 in vitro Methods 0.000 description 7\n\n238000001727 in vivo Methods 0.000 description 7\n\n230000003993 interaction Effects 0.000 description 7\n\n238000002844 melting Methods 0.000 description 7\n\n230000008018 melting Effects 0.000 description 7\n\n229960004023 minocycline Drugs 0.000 description 7\n\n229960001727 tretinoin Drugs 0.000 description 7\n\nQTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6\n\n239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 6\n\nZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 6\n\nARIWANIATODDMH-UHFFFAOYSA-N Lauric acid monoglyceride Natural products CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 6\n\n239000004962 Polyamide-imide Substances 0.000 description 6\n\nXAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 6\n\n238000004458 analytical method Methods 0.000 description 6\n\n239000001273 butane Substances 0.000 description 6\n\nKRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6\n\n235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 6\n\n230000001815 facial effect Effects 0.000 description 6\n\n238000004128 high performance liquid chromatography Methods 0.000 description 6\n\n239000004292 methyl p-hydroxybenzoate Substances 0.000 description 6\n\n235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 6\n\n229960002216 methylparaben Drugs 0.000 description 6\n\nOFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 6\n\nBDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 6\n\nFJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 6\n\n229920002312 polyamide-imide Polymers 0.000 description 6\n\n229960004889 salicylic acid Drugs 0.000 description 6\n\n239000000126 substance Substances 0.000 description 6\n\n206010037888 Rash pustular Diseases 0.000 description 5\n\n230000015572 biosynthetic process Effects 0.000 description 5\n\n230000001186 cumulative effect Effects 0.000 description 5\n\n230000002500 effect on skin Effects 0.000 description 5\n\n238000011156 evaluation Methods 0.000 description 5\n\n239000003906 humectant Substances 0.000 description 5\n\n239000007788 liquid Substances 0.000 description 5\n\n238000002156 mixing Methods 0.000 description 5\n\n229940068196 placebo Drugs 0.000 description 5\n\n239000000902 placebo Substances 0.000 description 5\n\n238000002360 preparation method Methods 0.000 description 5\n\n125000006239 protecting group Chemical group 0.000 description 5\n\n208000029561 pustule Diseases 0.000 description 5\n\n238000003860 storage Methods 0.000 description 5\n\n229940042129 topical gel Drugs 0.000 description 5\n\nNBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4\n\nOGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 4\n\nMYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 4\n\n238000002425 crystallisation Methods 0.000 description 4\n\n230000008025 crystallization Effects 0.000 description 4\n\nXBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4\n\n150000002148 esters Chemical class 0.000 description 4\n\n238000002474 experimental method Methods 0.000 description 4\n\n239000004615 ingredient Substances 0.000 description 4\n\nNNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 4\n\nJVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4\n\nBDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4\n\n238000012986 modification Methods 0.000 description 4\n\n230000004048 modification Effects 0.000 description 4\n\n239000008259 solid foam Substances 0.000 description 4\n\nUCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4\n\n229960000565 tazarotene Drugs 0.000 description 4\n\n210000002700 urine Anatomy 0.000 description 4\n\n230000004580 weight loss Effects 0.000 description 4\n\n239000000230 xanthan gum Substances 0.000 description 4\n\n229920001285 xanthan gum Polymers 0.000 description 4\n\n229940082509 xanthan gum Drugs 0.000 description 4\n\n235000010493 xanthan gum Nutrition 0.000 description 4\n\nXMAYWYJOQHXEEK-ZEQKJWHPSA-N (2S,4R)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@H]1O[C@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-ZEQKJWHPSA-N 0.000 description 3\n\nOFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3\n\n229910019142 PO4 Inorganic materials 0.000 description 3\n\n239000002253 acid Substances 0.000 description 3\n\n239000004480 active ingredient Substances 0.000 description 3\n\n229960002916 adapalene Drugs 0.000 description 3\n\nLZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 3\n\n238000000540 analysis of variance Methods 0.000 description 3\n\n230000008859 change Effects 0.000 description 3\n\n239000007979 citrate buffer Substances 0.000 description 3\n\n230000000052 comparative effect Effects 0.000 description 3\n\n238000009792 diffusion process Methods 0.000 description 3\n\n235000011187 glycerol Nutrition 0.000 description 3\n\n230000035515 penetration Effects 0.000 description 3\n\n230000000144 pharmacologic effect Effects 0.000 description 3\n\n239000010452 phosphate Substances 0.000 description 3\n\n125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3\n\n239000002904 solvent Substances 0.000 description 3\n\nIHCDKJZZFOUARO-UHFFFAOYSA-M sulfacetamide sodium Chemical compound O.[Na+].CC(=O)[N-]S(=O)(=O)C1=CC=C(N)C=C1 IHCDKJZZFOUARO-UHFFFAOYSA-M 0.000 description 3\n\n238000011200 topical administration Methods 0.000 description 3\n\nMMRINLZOZVAPDZ-LSGRDSQZSA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;chloride Chemical compound Cl.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 MMRINLZOZVAPDZ-LSGRDSQZSA-N 0.000 description 2\n\nARIWANIATODDMH-AWEZNQCLSA-N 1-lauroyl-sn-glycerol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)CO ARIWANIATODDMH-AWEZNQCLSA-N 0.000 description 2\n\nHZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2\n\nXMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2\n\nOSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2\n\nQGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2\n\n239000004184 Avoparcin Substances 0.000 description 2\n\n108010001478 Bacitracin Proteins 0.000 description 2\n\nSPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 description 2\n\n239000004322 Butylated hydroxytoluene Substances 0.000 description 2\n\nNLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2\n\n229930186147 Cephalosporin Natural products 0.000 description 2\n\nRGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2\n\nMQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 2\n\nVZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\\C=C\\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2\n\nIECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 description 2\n\nCEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2\n\n229930182566 Gentamicin Natural products 0.000 description 2\n\nAEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2\n\nVEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2\n\nKFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2\n\nGSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 2\n\nAFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2\n\nRJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 2\n\nMVTQIFVKRXBCHS-SMMNFGSLSA-N N-[(3S,6S,12R,15S,16R,19S,22S)-3-benzyl-12-ethyl-4,16-dimethyl-2,5,11,14,18,21,24-heptaoxo-19-phenyl-17-oxa-1,4,10,13,20-pentazatricyclo[20.4.0.06,10]hexacosan-15-yl]-3-hydroxypyridine-2-carboxamide (10R,11R,12E,17E,19E,21S)-21-hydroxy-11,19-dimethyl-10-propan-2-yl-9,26-dioxa-3,15,28-triazatricyclo[23.2.1.03,7]octacosa-1(27),6,12,17,19,25(28)-hexaene-2,8,14,23-tetrone Chemical compound CC(C)[C@H]1OC(=O)C2=CCCN2C(=O)c2coc(CC(=O)C[C@H](O)\\C=C(/C)\\C=C\\CNC(=O)\\C=C\\[C@H]1C)n2.CC[C@H]1NC(=O)[C@@H](NC(=O)c2ncccc2O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@@H]2CC(=O)CCN2C(=O)[C@H](Cc2ccccc2)N(C)C(=O)[C@@H]2CCCN2C1=O)c1ccccc1 MVTQIFVKRXBCHS-SMMNFGSLSA-N 0.000 description 2\n\n229930182555 Penicillin Natural products 0.000 description 2\n\nJGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2\n\n208000003251 Pruritus Diseases 0.000 description 2\n\nLCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2\n\nQAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2\n\n108010053950 Teicoplanin Proteins 0.000 description 2\n\nWKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 2\n\n108010059993 Vancomycin Proteins 0.000 description 2\n\n108010080702 Virginiamycin Proteins 0.000 description 2\n\n239000004188 Virginiamycin Substances 0.000 description 2\n\nRRZFQNYMUQPMHE-HYEGCIPRSA-N [(2r,3r,4s,5r,6r)-6-[(1s,2s)-2-chloro-1-[[(2s,4r)-1-methyl-4-propylpyrrolidine-2-carbonyl]amino]propyl]-4,5-dihydroxy-2-methylsulfanyloxan-3-yl] dihydrogen phosphate;(2e,4e,6e,8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid Chemical compound OC(=O)\\C=C(/C)\\C=C\\C=C(/C)\\C=C\\C1=C(C)CCCC1(C)C.CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@@H](SC)O1 RRZFQNYMUQPMHE-HYEGCIPRSA-N 0.000 description 2\n\n125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2\n\n125000002252 acyl group Chemical group 0.000 description 2\n\nFPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\\C=C(/C)\\C=C\\C=C(/C)\\C=C\\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2\n\n229910000147 aluminium phosphate Inorganic materials 0.000 description 2\n\n229960004821 amikacin Drugs 0.000 description 2\n\nLKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 2\n\n229960000723 ampicillin Drugs 0.000 description 2\n\nAVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2\n\n230000000844 anti-bacterial effect Effects 0.000 description 2\n\n230000000843 anti-fungal effect Effects 0.000 description 2\n\n239000004599 antimicrobial Substances 0.000 description 2\n\n239000007864 aqueous solution Substances 0.000 description 2\n\nJWFVWARSGMYXRN-HTQQBIQNSA-N avoparcin Chemical compound O([C@H]1[C@H](C(N[C@H](C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(N[C@H](C4=CC(O)=CC(O)=C4C=4C(O)=CC=C3C=4)C(O)=O)=O)CC3=C(O[C@@H]4O[C@@H](C)[C@H](O)[C@H](N)C4)C=C(C(=C3)Cl)OC=3C=C2C=C(C=3O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2O[C@@H](C)[C@H](O)[C@H](N)C2)OC2=CC=C1C=C2)C=1C=CC(O)=CC=1)=O)NC(=O)[C@@H](NC)C=1C=CC(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)=CC=1)[C@@H]1O[C@@H](CO)[C@H](O)[C@@H](O)[C@H]1O JWFVWARSGMYXRN-HTQQBIQNSA-N 0.000 description 2\n\n229950001335 avoparcin Drugs 0.000 description 2\n\n235000019377 avoparcin Nutrition 0.000 description 2\n\n108010053278 avoparcin Proteins 0.000 description 2\n\n229960003071 bacitracin Drugs 0.000 description 2\n\n229930184125 bacitracin Natural products 0.000 description 2\n\nCLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 2\n\n230000008901 benefit Effects 0.000 description 2\n\nWPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2\n\nAPQDBWGZCQHKHQ-SHSUDHJHSA-N benzoyl benzenecarboperoxoate;[(2r,3r,4s,5r,6r)-6-[(1s,2s)-2-chloro-1-[[(2s,4r)-1-methyl-4-propylpyrrolidine-2-carbonyl]amino]propyl]-4,5-dihydroxy-2-methylsulfanyloxan-3-yl] dihydrogen phosphate Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1.CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@@H](SC)O1 APQDBWGZCQHKHQ-SHSUDHJHSA-N 0.000 description 2\n\n235000010354 butylated hydroxytoluene Nutrition 0.000 description 2\n\n229940095259 butylated hydroxytoluene Drugs 0.000 description 2\n\nPPKJUHVNTMYXOD-PZGPJMECSA-N c49ws9n75l Chemical compound O=C([C@@H]1N(C2=O)CC[C@H]1S(=O)(=O)CCN(CC)CC)O[C@H](C(C)C)[C@H](C)\\C=C\\C(=O)NC\\C=C\\C(\\C)=C\\[C@@H](O)CC(=O)CC1=NC2=CO1.N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2C[C@@H](CS[C@H]3C4CCN(CC4)C3)C(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O PPKJUHVNTMYXOD-PZGPJMECSA-N 0.000 description 2\n\n229960003669 carbenicillin Drugs 0.000 description 2\n\nFPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 2\n\n229960002100 cefepime Drugs 0.000 description 2\n\n229960004261 cefotaxime Drugs 0.000 description 2\n\nAZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 2\n\n229960000466 cefpirome Drugs 0.000 description 2\n\nDKOQGJHPHLTOJR-WHRDSVKCSA-N cefpirome Chemical compound N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)\\C(=N/OC)C1=CSC(N)=N1 DKOQGJHPHLTOJR-WHRDSVKCSA-N 0.000 description 2\n\n229960004755 ceftriaxone Drugs 0.000 description 2\n\nVAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 2\n\n229940124587 cephalosporin Drugs 0.000 description 2\n\n150000001780 cephalosporins Chemical class 0.000 description 2\n\nDDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 description 2\n\n229960005091 chloramphenicol Drugs 0.000 description 2\n\nWIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2\n\n229960003405 ciprofloxacin Drugs 0.000 description 2\n\n235000015165 citric acid Nutrition 0.000 description 2\n\n229940023968 clindamycin / tretinoin Drugs 0.000 description 2\n\n229960001200 clindamycin hydrochloride Drugs 0.000 description 2\n\n230000007797 corrosion Effects 0.000 description 2\n\n238000005260 corrosion Methods 0.000 description 2\n\n229960000860 dapsone Drugs 0.000 description 2\n\n230000003247 decreasing effect Effects 0.000 description 2\n\n229960000935 dehydrated alcohol Drugs 0.000 description 2\n\n238000006073 displacement reaction Methods 0.000 description 2\n\n238000009513 drug distribution Methods 0.000 description 2\n\n229960000740 enrofloxacin Drugs 0.000 description 2\n\n235000019253 formic acid Nutrition 0.000 description 2\n\n125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2\n\n125000000524 functional group Chemical group 0.000 description 2\n\n229960004675 fusidic acid Drugs 0.000 description 2\n\nIECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 2\n\n239000000499 gel Substances 0.000 description 2\n\n229940068939 glyceryl monolaurate Drugs 0.000 description 2\n\n238000011194 good manufacturing practice Methods 0.000 description 2\n\n239000008240 homogeneous mixture Substances 0.000 description 2\n\nPOUMFISTNHIPTI-BOMBIWCESA-N hydron;(2s,4r)-n-[(1r,2r)-2-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide;chloride Chemical compound Cl.CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 POUMFISTNHIPTI-BOMBIWCESA-N 0.000 description 2\n\n229960002182 imipenem Drugs 0.000 description 2\n\nZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\\N=C\\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 2\n\n229910052738 indium Inorganic materials 0.000 description 2\n\nSUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2\n\n239000001282 iso-butane Substances 0.000 description 2\n\n229960003350 isoniazid Drugs 0.000 description 2\n\nQRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 2\n\n229960004125 ketoconazole Drugs 0.000 description 2\n\n239000004310 lactic acid Substances 0.000 description 2\n\n235000014655 lactic acid Nutrition 0.000 description 2\n\n229960003376 levofloxacin Drugs 0.000 description 2\n\n229960001595 lincomycin hydrochloride Drugs 0.000 description 2\n\n238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2\n\n239000006210 lotion Substances 0.000 description 2\n\n238000004949 mass spectrometry Methods 0.000 description 2\n\n239000000463 material Substances 0.000 description 2\n\n238000005259 measurement Methods 0.000 description 2\n\n238000002483 medication Methods 0.000 description 2\n\n229960002260 meropenem Drugs 0.000 description 2\n\nDMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 2\n\n229960003085 meticillin Drugs 0.000 description 2\n\nTXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical group OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2\n\nFUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2\n\nZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 2\n\n125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2\n\n229940049954 penicillin Drugs 0.000 description 2\n\n230000004526 pharmaceutical effect Effects 0.000 description 2\n\n239000000546 pharmaceutical excipient Substances 0.000 description 2\n\nNBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2\n\n229960002292 piperacillin Drugs 0.000 description 2\n\nWCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 description 2\n\n235000019260 propionic acid Nutrition 0.000 description 2\n\n229960005206 pyrazinamide Drugs 0.000 description 2\n\nIPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 description 2\n\n238000003908 quality control method Methods 0.000 description 2\n\nIUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2\n\n150000007660 quinolones Chemical class 0.000 description 2\n\n108010071077 quinupristin-dalfopristin Proteins 0.000 description 2\n\n229960001225 rifampicin Drugs 0.000 description 2\n\nJQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\\C=C\\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\\C=N\\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 2\n\n208000017520 skin disease Diseases 0.000 description 2\n\n239000007787 solid Substances 0.000 description 2\n\n239000007921 spray Substances 0.000 description 2\n\n238000013112 stability test Methods 0.000 description 2\n\n229910001220 stainless steel Inorganic materials 0.000 description 2\n\n239000010935 stainless steel Substances 0.000 description 2\n\n238000003756 stirring Methods 0.000 description 2\n\n229960005322 streptomycin Drugs 0.000 description 2\n\n229940124530 sulfonamide Drugs 0.000 description 2\n\n150000003456 sulfonamides Chemical class 0.000 description 2\n\n238000001356 surgical procedure Methods 0.000 description 2\n\n229940020707 synercid Drugs 0.000 description 2\n\n238000003786 synthesis reaction Methods 0.000 description 2\n\n230000009885 systemic effect Effects 0.000 description 2\n\n229960001608 teicoplanin Drugs 0.000 description 2\n\n230000001225 therapeutic effect Effects 0.000 description 2\n\n125000003396 thiol group Chemical group [H]S* 0.000 description 2\n\nOHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 2\n\n229960004659 ticarcillin Drugs 0.000 description 2\n\n210000001519 tissue Anatomy 0.000 description 2\n\n229940100613 topical solution Drugs 0.000 description 2\n\nVZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2\n\n125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 2\n\nIEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 2\n\n229960001082 trimethoprim Drugs 0.000 description 2\n\n229960003165 vancomycin Drugs 0.000 description 2\n\nMYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2\n\nMYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 2\n\n229960003842 virginiamycin Drugs 0.000 description 2\n\n235000019373 virginiamycin Nutrition 0.000 description 2\n\nQBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1\n\nMIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1\n\nBJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1\n\nWBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\\C=C\\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1\n\nAMMPLVWPWSYRDR-UHFFFAOYSA-N 1-methylbicyclo[2.2.2]oct-2-ene-4-carboxylic acid Chemical compound C1CC2(C(O)=O)CCC1(C)C=C2 AMMPLVWPWSYRDR-UHFFFAOYSA-N 0.000 description 1\n\nFPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1\n\nUPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical group C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1\n\nXLZYKTYMLBOINK-UHFFFAOYSA-N 3-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C(=O)C=2C=CC(O)=CC=2)=C1 XLZYKTYMLBOINK-UHFFFAOYSA-N 0.000 description 1\n\nBMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1\n\nZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1\n\nZRVIYEJYXIDATJ-UHFFFAOYSA-N 4-Heptyloxybenzoic acid Chemical compound CCCCCCCOC1=CC=C(C(O)=O)C=C1 ZRVIYEJYXIDATJ-UHFFFAOYSA-N 0.000 description 1\n\nRJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 1\n\nSHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\\C)/C=C/C=C(/C)\\C=C\\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1\n\nQTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1\n\n241000186361 Actinobacteria <class> Species 0.000 description 1\n\nQGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1\n\n206010048943 Application site dryness Diseases 0.000 description 1\n\n206010003051 Application site pain Diseases 0.000 description 1\n\n206010003055 Application site reaction Diseases 0.000 description 1\n\n208000004926 Bacterial Vaginosis Diseases 0.000 description 1\n\n239000005711 Benzoic acid Substances 0.000 description 1\n\nWWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1\n\nWBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1\n\nKRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1\n\nGTNDZRUWKHDICY-DJHAJVGHSA-N Clindamycin palmitate hydrochloride Chemical compound Cl.O1[C@H](SC)[C@H](OC(=O)CCCCCCCCCCCCCCC)[C@@H](O)[C@@H](O)[C@H]1[C@@H]([C@H](C)Cl)NC(=O)[C@H]1N(C)C[C@H](CCC)C1 GTNDZRUWKHDICY-DJHAJVGHSA-N 0.000 description 1\n\n238000000959 CochranâMantelâHaenszel (CMH) test Methods 0.000 description 1\n\n208000011231 Crohn disease Diseases 0.000 description 1\n\nRGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Chemical group OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1\n\nFEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1\n\n206010012735 Diarrhoea Diseases 0.000 description 1\n\n206010015150 Erythema Diseases 0.000 description 1\n\nBDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1\n\n206010017533 Fungal infection Diseases 0.000 description 1\n\n241000233866 Fungi Species 0.000 description 1\n\nWHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical group OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1\n\n206010019233 Headaches Diseases 0.000 description 1\n\n208000022559 Inflammatory bowel disease Diseases 0.000 description 1\n\nWHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1\n\nJVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1\n\n239000012901 Milli-Q water Substances 0.000 description 1\n\n239000004909 Moisturizer Substances 0.000 description 1\n\nTXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Chemical group OC(=O)\\C=C/C=C\\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1\n\n208000031888 Mycoses Diseases 0.000 description 1\n\nMBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1\n\nGRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1\n\n229920003171 Poly (ethylene oxide) Polymers 0.000 description 1\n\n229920001213 Polysorbate 20 Polymers 0.000 description 1\n\nXBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1\n\nIWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1\n\nFAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1\n\n235000021355 Stearic acid Nutrition 0.000 description 1\n\n238000000692 Student's t-test Methods 0.000 description 1\n\nKDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1\n\nFEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1\n\nGSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1\n\nXLYOFNOQVPJJNP-PWCQTSIFSA-N Tritiated water Chemical compound [3H]O[3H] XLYOFNOQVPJJNP-PWCQTSIFSA-N 0.000 description 1\n\n208000037009 Vaginitis bacterial Diseases 0.000 description 1\n\n235000019013 Viburnum opulus Nutrition 0.000 description 1\n\n244000071378 Viburnum opulus Species 0.000 description 1\n\n210000001015 abdomen Anatomy 0.000 description 1\n\n230000002378 acidificating effect Effects 0.000 description 1\n\n239000000853 adhesive Substances 0.000 description 1\n\n230000001070 adhesive effect Effects 0.000 description 1\n\n239000003513 alkali Substances 0.000 description 1\n\n229910001413 alkali metal ion Inorganic materials 0.000 description 1\n\n229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1\n\n150000005215 alkyl ethers Chemical class 0.000 description 1\n\n150000001280 alpha hydroxy acids Chemical class 0.000 description 1\n\nBJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1\n\n229910021529 ammonia Inorganic materials 0.000 description 1\n\n238000012801 analytical assay Methods 0.000 description 1\n\n239000003098 androgen Substances 0.000 description 1\n\n230000003255 anti-acne Effects 0.000 description 1\n\n230000000845 anti-microbial effect Effects 0.000 description 1\n\n239000003443 antiviral agent Substances 0.000 description 1\n\n239000008346 aqueous phase Substances 0.000 description 1\n\n239000012298 atmosphere Substances 0.000 description 1\n\n230000001580 bacterial effect Effects 0.000 description 1\n\n238000003287 bathing Methods 0.000 description 1\n\nSRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1\n\n229940092714 benzenesulfonic acid Drugs 0.000 description 1\n\n235000010233 benzoic acid Nutrition 0.000 description 1\n\n229960003328 benzoyl peroxide Drugs 0.000 description 1\n\nGONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1\n\n125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1\n\n150000001277 beta hydroxy acids Chemical class 0.000 description 1\n\n229920001400 block copolymer Polymers 0.000 description 1\n\n239000008280 blood Substances 0.000 description 1\n\n210000004369 blood Anatomy 0.000 description 1\n\n239000007853 buffer solution Substances 0.000 description 1\n\n230000003139 buffering effect Effects 0.000 description 1\n\nKDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1\n\n235000014171 carbonated beverage Nutrition 0.000 description 1\n\nBVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1\n\n150000004649 carbonic acid derivatives Chemical class 0.000 description 1\n\n125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1\n\n235000013985 cinnamic acid Nutrition 0.000 description 1\n\n229930016911 cinnamic acid Natural products 0.000 description 1\n\n229940021231 clearskin Drugs 0.000 description 1\n\nKDLRVYVGXIQJDK-NOWPCOIGSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)NC(C(C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-NOWPCOIGSA-N 0.000 description 1\n\n229960004714 clindamycin palmitate Drugs 0.000 description 1\n\nOYSKUZDIHNKWLV-PRUAPSLNSA-N clindamycin palmitate Chemical compound O1[C@H](SC)[C@H](OC(=O)CCCCCCCCCCCCCCC)[C@@H](O)[C@@H](O)[C@H]1[C@@H]([C@H](C)Cl)NC(=O)[C@H]1N(C)C[C@H](CCC)C1 OYSKUZDIHNKWLV-PRUAPSLNSA-N 0.000 description 1\n\n229960000792 clindamycin palmitate hydrochloride Drugs 0.000 description 1\n\n206010009887 colitis Diseases 0.000 description 1\n\n238000013329 compounding Methods 0.000 description 1\n\n238000001816 cooling Methods 0.000 description 1\n\n230000002596 correlated effect Effects 0.000 description 1\n\n230000000875 corresponding effect Effects 0.000 description 1\n\n239000002537 cosmetic Substances 0.000 description 1\n\n238000002788 crimping Methods 0.000 description 1\n\n230000034994 death Effects 0.000 description 1\n\n231100000517 death Toxicity 0.000 description 1\n\n239000008380 degradant Substances 0.000 description 1\n\n230000000881 depressing effect Effects 0.000 description 1\n\n238000011161 development Methods 0.000 description 1\n\n235000014113 dietary fatty acids Nutrition 0.000 description 1\n\nZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1\n\n238000004090 dissolution Methods 0.000 description 1\n\n208000002173 dizziness Diseases 0.000 description 1\n\nMOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical group CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1\n\n238000012377 drug delivery Methods 0.000 description 1\n\n229940088679 drug related substance Drugs 0.000 description 1\n\n235000014103 egg white Nutrition 0.000 description 1\n\n210000000969 egg white Anatomy 0.000 description 1\n\n230000007613 environmental effect Effects 0.000 description 1\n\n231100000321 erythema Toxicity 0.000 description 1\n\n239000000262 estrogen Substances 0.000 description 1\n\n229940011871 estrogen Drugs 0.000 description 1\n\nAFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1\n\nCCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1\n\n230000029142 excretion Effects 0.000 description 1\n\n239000000284 extract Substances 0.000 description 1\n\n238000000605 extraction Methods 0.000 description 1\n\n239000000194 fatty acid Substances 0.000 description 1\n\n229930195729 fatty acid Natural products 0.000 description 1\n\n150000004665 fatty acids Chemical class 0.000 description 1\n\n239000012458 free base Substances 0.000 description 1\n\n239000001530 fumaric acid Substances 0.000 description 1\n\n235000011087 fumaric acid Nutrition 0.000 description 1\n\n239000011521 glass Substances 0.000 description 1\n\n239000000174 gluconic acid Chemical group 0.000 description 1\n\n235000012208 gluconic acid Nutrition 0.000 description 1\n\n239000004220 glutamic acid Chemical group 0.000 description 1\n\n235000013922 glutamic acid Nutrition 0.000 description 1\n\n230000005484 gravity Effects 0.000 description 1\n\n230000036541 health Effects 0.000 description 1\n\n150000004679 hydroxides Chemical class 0.000 description 1\n\n125000004356 hydroxy functional group Chemical group O* 0.000 description 1\n\n125000002887 hydroxy group Chemical group [H]O* 0.000 description 1\n\n230000000977 initiatory effect Effects 0.000 description 1\n\n238000002347 injection Methods 0.000 description 1\n\n239000007924 injection Substances 0.000 description 1\n\n230000002452 interceptive effect Effects 0.000 description 1\n\n230000007794 irritation Effects 0.000 description 1\n\n230000007803 itching Effects 0.000 description 1\n\n238000002372 labelling Methods 0.000 description 1\n\n239000004922 lacquer Substances 0.000 description 1\n\n238000011031 large-scale manufacturing process Methods 0.000 description 1\n\n229940100556 laureth-23 Drugs 0.000 description 1\n\n230000000670 limiting effect Effects 0.000 description 1\n\n238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1\n\n239000007791 liquid phase Substances 0.000 description 1\n\n238000005567 liquid scintillation counting Methods 0.000 description 1\n\nVZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1\n\n239000011976 maleic acid Substances 0.000 description 1\n\n239000001630 malic acid Substances 0.000 description 1\n\n235000011090 malic acid Nutrition 0.000 description 1\n\n229960002510 mandelic acid Drugs 0.000 description 1\n\n238000004519 manufacturing process Methods 0.000 description 1\n\n229910052751 metal Inorganic materials 0.000 description 1\n\n239000002184 metal Substances 0.000 description 1\n\n229910021645 metal ion Inorganic materials 0.000 description 1\n\n229940098779 methanesulfonic acid Drugs 0.000 description 1\n\n125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1\n\nWBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1\n\n244000005700 microbiome Species 0.000 description 1\n\n235000013336 milk Nutrition 0.000 description 1\n\n239000008267 milk Substances 0.000 description 1\n\n210000004080 milk Anatomy 0.000 description 1\n\n235000020166 milkshake Nutrition 0.000 description 1\n\n150000007522 mineralic acids Chemical class 0.000 description 1\n\n230000001333 moisturizer Effects 0.000 description 1\n\n238000012544 monitoring process Methods 0.000 description 1\n\nKVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1\n\n239000000842 neuromuscular blocking agent Substances 0.000 description 1\n\n229910017604 nitric acid Inorganic materials 0.000 description 1\n\n229940064438 nizoral Drugs 0.000 description 1\n\n238000002414 normal-phase solid-phase extraction Methods 0.000 description 1\n\nQIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1\n\nOQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1\n\n150000007524 organic acids Chemical class 0.000 description 1\n\n235000005985 organic acids Nutrition 0.000 description 1\n\n150000007530 organic bases Chemical class 0.000 description 1\n\n238000010979 pH adjustment Methods 0.000 description 1\n\n239000006174 pH buffer Substances 0.000 description 1\n\n231100000435 percutaneous penetration Toxicity 0.000 description 1\n\n230000035699 permeability Effects 0.000 description 1\n\n239000008177 pharmaceutical agent Substances 0.000 description 1\n\n239000008194 pharmaceutical composition Substances 0.000 description 1\n\nUYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1\n\n239000008055 phosphate buffer solution Substances 0.000 description 1\n\n150000003014 phosphoric acid esters Chemical class 0.000 description 1\n\nIUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1\n\n239000004033 plastic Substances 0.000 description 1\n\n229920003023 plastic Polymers 0.000 description 1\n\n229920001983 poloxamer Polymers 0.000 description 1\n\n239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1\n\n235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1\n\n239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1\n\n235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1\n\n229940068977 polysorbate 20 Drugs 0.000 description 1\n\n229940068968 polysorbate 80 Drugs 0.000 description 1\n\n229920000053 polysorbate 80 Polymers 0.000 description 1\n\n229940068965 polysorbates Drugs 0.000 description 1\n\nWSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1\n\n229940107700 pyruvic acid Drugs 0.000 description 1\n\n238000011002 quantification Methods 0.000 description 1\n\n230000002285 radioactive effect Effects 0.000 description 1\n\n238000011084 recovery Methods 0.000 description 1\n\n230000002829 reductive effect Effects 0.000 description 1\n\n238000012827 research and development Methods 0.000 description 1\n\n229930002330 retinoic acid Natural products 0.000 description 1\n\n229960003471 retinol Drugs 0.000 description 1\n\n235000020944 retinol Nutrition 0.000 description 1\n\n239000011607 retinol Substances 0.000 description 1\n\n230000002441 reversible effect Effects 0.000 description 1\n\n238000012552 review Methods 0.000 description 1\n\n238000000518 rheometry Methods 0.000 description 1\n\n238000005070 sampling Methods 0.000 description 1\n\n238000009517 secondary packaging Methods 0.000 description 1\n\n239000008257 shaving cream Substances 0.000 description 1\n\n238000007711 solidification Methods 0.000 description 1\n\n230000008023 solidification Effects 0.000 description 1\n\n241000894007 species Species 0.000 description 1\n\n238000005507 spraying Methods 0.000 description 1\n\n238000010186 staining Methods 0.000 description 1\n\n239000012086 standard solution Substances 0.000 description 1\n\n239000008117 stearic acid Chemical group 0.000 description 1\n\n229940012831 stearyl alcohol Drugs 0.000 description 1\n\n150000003431 steroids Chemical class 0.000 description 1\n\n239000000758 substrate Substances 0.000 description 1\n\n239000006228 supernatant Substances 0.000 description 1\n\n239000013589 supplement Substances 0.000 description 1\n\n208000024891 symptom Diseases 0.000 description 1\n\n239000011975 tartaric acid Substances 0.000 description 1\n\n235000002906 tartaric acid Nutrition 0.000 description 1\n\n230000002277 temperature effect Effects 0.000 description 1\n\nBWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\\C=C\\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1\n\n125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1\n\n238000002560 therapeutic procedure Methods 0.000 description 1\n\n201000004647 tinea pedis Diseases 0.000 description 1\n\nJOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1\n\n239000006208 topical dosage form Substances 0.000 description 1\n\nLENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1\n\n229960000281 trometamol Drugs 0.000 description 1\n\n230000001018 virulence Effects 0.000 description 1\n\n238000011179 visual inspection Methods 0.000 description 1\n\n238000003260 vortexing Methods 0.000 description 1\n\n239000008256 whipped cream Substances 0.000 description 1\n\nImages\n\nClassifications\n\nA—HUMAN NECESSITIES\n\nA61—MEDICAL OR VETERINARY SCIENCE; HYGIENE\n\nA61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES\n\nA61K31/00—Medicinal preparations containing organic active ingredients\n\nA61K31/33—Heterocyclic compounds\n\nA61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins\n\nA61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil\n\nA61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim\n\nA—HUMAN NECESSITIES\n\nA61—MEDICAL OR VETERINARY SCIENCE; HYGIENE\n\nA61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES\n\nA61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00Â -Â A61K41/00\n\nA61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca\n\nA—HUMAN NECESSITIES\n\nA61—MEDICAL OR VETERINARY SCIENCE; HYGIENE\n\nA61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES\n\nA61K8/00—Cosmetics or similar toiletry preparations\n\nA61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form\n\nA61K8/04—Dispersions; Emulsions\n\nA61K8/046—Aerosols; Foams\n\nA—HUMAN NECESSITIES\n\nA61—MEDICAL OR VETERINARY SCIENCE; HYGIENE\n\nA61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES\n\nA61K8/00—Cosmetics or similar toiletry preparations\n\nA61K8/18—Cosmetics or similar toiletry preparations characterised by the composition\n\nA61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds\n\nA61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen\n\nA61K8/38—Percompounds, e.g. peracids\n\nA—HUMAN NECESSITIES\n\nA61—MEDICAL OR VETERINARY SCIENCE; HYGIENE\n\nA61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES\n\nA61K8/00—Cosmetics or similar toiletry preparations\n\nA61K8/18—Cosmetics or similar toiletry preparations characterised by the composition\n\nA61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds\n\nA61K8/67—Vitamins\n\nA61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal\n\nA—HUMAN NECESSITIES\n\nA61—MEDICAL OR VETERINARY SCIENCE; HYGIENE\n\nA61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES\n\nA61K9/00—Medicinal preparations characterised by special physical form\n\nA61K9/10—Dispersions; Emulsions\n\nA61K9/12—Aerosols; Foams\n\nA—HUMAN NECESSITIES\n\nA61—MEDICAL OR VETERINARY SCIENCE; HYGIENE\n\nA61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES\n\nA61K9/00—Medicinal preparations characterised by special physical form\n\nA61K9/10—Dispersions; Emulsions\n\nA61K9/12—Aerosols; Foams\n\nA61K9/122—Foams; Dry foams\n\nA—HUMAN NECESSITIES\n\nA61—MEDICAL OR VETERINARY SCIENCE; HYGIENE\n\nA61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS\n\nA61P17/00—Drugs for dermatological disorders\n\nA—HUMAN NECESSITIES\n\nA61—MEDICAL OR VETERINARY SCIENCE; HYGIENE\n\nA61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS\n\nA61P17/00—Drugs for dermatological disorders\n\nA61P17/10—Anti-acne agents\n\nA—HUMAN NECESSITIES\n\nA61—MEDICAL OR VETERINARY SCIENCE; HYGIENE\n\nA61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS\n\nA61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics\n\nA—HUMAN NECESSITIES\n\nA61—MEDICAL OR VETERINARY SCIENCE; HYGIENE\n\nA61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS\n\nA61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics\n\nA61P31/04—Antibacterial agents\n\nA—HUMAN NECESSITIES\n\nA61—MEDICAL OR VETERINARY SCIENCE; HYGIENE\n\nA61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS\n\nA61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00\n\nA—HUMAN NECESSITIES\n\nA61—MEDICAL OR VETERINARY SCIENCE; HYGIENE\n\nA61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS\n\nA61Q19/00—Preparations for care of the skin\n\nDefinitions\n\nthe present invention relates to topical delivery of at least one pharmaceutically active compound, especially clindamycin or its pharmaceutically acceptable salt or a prodrug thereof, alone or in combination with another pharmaceutically active compound.\n\ncomposition should also have desirable cosmetic characteristics. Application should be easy, smooth, and should not leave a noticeable residue on the surface of the skin. Moreover, the composition should not cause irritation, discomfort, or inconvenience.\n\nCleocin TÂ® manufactured by Pharmacia-Upjohn, contains clindamycin phosphate, which is inactive in vitro, but is hydrolyzed in vivo to the antibacterially active clindamycin. Cleocin TÂ® is currently available as a gel, a lotion, and a topical solution, and is used for topical treatment of acne vulgaris.\n\nLotion and gel topical dosage forms have the disadvantage of extended rub-in and may leave oily residues.\n\nthe solution form readily runs off the site of application, and therefore it is difficult to apply controlled amounts using the solution form.\n\nthe present invention overcomes these disadvantages by providing a composition having at least one pharmaceutically active compound, which is useful for topical administration as described herein, as a foam that is a non-runny, easy to apply, and uses a low residue vehicle.\n\na foam that is a non-runny, easy to apply, and uses a low residue vehicle.\n\nbody heat causes the foam structure to break down and deposit the active ingredient(s) in the form of a vehicle resembling a solution.\n\nthe foam composition provides good control of the application of a small amount of product to the desired area.\n\nthe present invention overcomes the disadvantages of the prior art by providing a pharmaceutically active composition, which is useful for topical administration, as a foam that is a non-runny, easy to apply, and uses a low residue vehicle.\n\nthe foam compositions of the present invention provide enhanced delivery of an active compound(s) across the skin compared to gel compositions and without the concomitant disadvantages associated with solution formulations (e.g., runniness, difficulty in applying controlled amounts).\n\nthe present invention provides a topical delivery composition in a pressurized container comprising:\n\nthe quick-breaking foaming agent comprises a C 1 âC 6 alcohol and water.\n\nthe quick-breaking foaming agent comprises a C 1 âC 6 alcohol, a C 14 âC 22 alcohol, water, and a surfactant.\n\nthe quick-breaking foaming agent does not contain a C 1 âC 6 alcohol.\n\nthe quick-breaking foaming agent can also comprise an emollient, which can also act as a humectant.\n\nthe quick-breaking foaming agent can also comprise a pH adjusting agent.\n\nthe at least one pharmaceutically active compound is an antibiotic agent.\n\nPreferred antibiotic agents include clindamycin or a pharmaceutically acceptable salt or ester thereof.\n\na particularly preferred antibiotic agent is clindamycin phosphate, which is inactive in vitro, but hydrolyzes in vivo to the antibacterially active clindamycin.\n\nthe at least one pharmaceutically active compound comprises a combination of active agents.\n\nAny combination of active agents suitable for topical administration can be used in the compositions of the present invention.\n\nthe combination of active agents comprises at least two agents selected from an antibiotic agent, an antifungal agent, a retinoid (e.g., tretinoin, tazarotene), a retinoid derivative (e.g., adapalene), salicylic acid, azelaic acid, sodium sulfacetamide, and benzoyl peroxide.\n\nSuitable antibiotic agents include, but are not limited to, clindamycin, erythromycin, tetracycline, minocycline, doxycycline, pharmaceutically acceptable salts thereof, and prodrugs thereof. More preferably, the combination of active agents comprises clindamycin phosphate and a member selected from an antifungal agent, a retinoid (e.g., tretinoin, tazarotene), a retinoid derivative (e.g., adapalene), salicylic acid, azelaic acid, sodium sulfacetamide, benzoyl peroxide, another antibiotic (e.g., erythromycin, tetracycline, minocycline, doxycycline), and mixtures thereof.\n\na retinoid e.g., tretinoin, tazarotene\n\na retinoid derivative e.g., adapalene\n\nsalicylic acid e.g., azela\n\nthe at least one pharmaceutically active compound comprises a combination of clindamycin phosphate and tretinoin. In another particularly preferred embodiment, the at least one pharmaceutically active compound comprises a combination of clindamycin phosphate and benzoyl peroxide.\n\ncompositions of the present invention comprising a combination of active agents preferably contain an effective amount of each agent, e.g., between about 0.01% to about 10% of an antibiotic, preferably between about 0.1% to about 5% of an antibiotic, any effective amount of salicylic acid or benzoyl peroxide, preferably between about 0.5% to about 10% w/w, and any effective amount of a retinoid or a retinoid derivative, preferably between about 0.01% to about 0.5% w/w.\n\nconcentrations of each agent above or below the effective amount are also within the scope of the present invention.\n\nthe pharmaceutically active compound is an antifungal agent.\n\nPreferred antifungal agents include ketoconazole, e.g., in the form of NizoralÂ®.\n\nthe pharmaceutically active compound comprises a combination of an antifungal agent and an agent selected from an antibiotic agent, a retinoid (e.g., tretinoin, tazarotene), a retinoid derivative (e.g., adapalene), salicylic acid, azelaic acid, sodium sulfacetamide, benzoyl peroxide, and mixtures thereof.\n\nSuitable antibiotic agents include, but are not limited to, clindamycin, erythromycin, tetracycline, minocycline, doxycycline, pharmaceutically acceptable salts thereof, and prodrugs thereof.\n\nthe present invention provides a method for modulating the foam breaking temperature of a quick-breaking temperature sensitive foam composition.\n\nthe foam breaking temperature is modulated by, for example, changing the C 1 âC 6 alcohol to water ratio in the quick-breaking temperature sensitive foam composition.\n\nthe present invention provides a method for the percutaneous treatment of acne, using, for example, the compositions of the present invention.\n\nthe acne treatment method generally involves applying a quick-breaking temperature sensitive foam composition comprising an effective amount of clindamycin or a pharmaceutially acceptable salt or a prodrug thereof to a subject in need of such treatment.\n\nthe quick-breaking temperature sensitive foam composition further comprises a retinoid (e.g., tretinoin, tazarotene).\n\nthe retinoid is present in an amount of from about 0.01% to about 0.1% w/w.\n\nthe quick-breaking temperature sensitive foam composition further comprises benzoyl peroxide.\n\nthe benzoyl peroxide is present in an amount of from about 0.5% to about 10% w/w.\n\nthe present invention provides a method for evaluating foam characteristics, the method comprising:\n\nthe present invention provides a use of a pharmaceutical composition in a pressurized container in the preparation of a medicament for the percutaneous treatment of acne, the composition comprising:\n\nFIG. 1 is a graph showing the effect of temperature on the clindamycin phosphate foam structure, which was determined by first dispensing approximately 2 grams of foam at 20Â° C. The foam was then placed in a controlled environment at the indicated temperatures and the time required to melt the foam to a liquid was determined.\n\nFIG. 2 shows one embodiment of a visual aid that can be used in evaluating foam structures.\n\nFIG. 3 is a graph showing the amount of clindamycin phosphate degradation at various pH and citrate buffer levels as described in Example 1.\n\nFIG. 4 is a graph showing the amount of clindamycin phosphate remaining at various times under various pH levels in cans at various temperatures.\n\nFIG. 5 shows stability data of clindamycin phosphate as determined in Example 4.\n\nFIG. 6 shows plasma clindamycin concentration as a function of time after application of clindamycin foam and ClindaGelTM.\n\nFIG. 7 shows a graph of the cumulative percutaneous absorption of clindamycin foam, ClindaGelTM, and Cleocin TÂ® solution over a 24-hour period. Each time-point represents the mean total absorption â standard error for 3 skin donors (3 replicates for each). *p â 0.05 (gel vs. foam); p â 0.06 (gel vs. solution); p>0.1 (foam vs. solution).\n\nFIG. 8 shows a graph of the flux profile for the percutaneous absorption of clindamycin foam, ClindaGelTM, and Cleocin TÂ® solution over a 24-hour period. Each time-point represents the mean absorption â standard error for 3 skin donors (3 replicates for each).\n\nFIG. 9 shows a graph of the distribution of clindamycin in different layers of the skin 24 hours after application of clindamycin foam, ClindaGelTM, and Cleocin TÂ® solution.\n\nactive agent active compound\n\nactive compound at least one pharmaceutically active compound\n\npharmaceutically active agent refers to a substance having a pharmaceutical, pharmacological or therapeutic effect.\n\nâHomogeneousâ means uniform throughout, i.e., a single phase mixture.\n\nâPharmaceutically acceptable saltâ of an active compound means a salt that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound.\n\nSuch salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic\n\nProdrug refers to any compound which releases an active agent in vivo when such prodrug is administered to a subject.\n\nProdrugs of an active agent are prepared by modifying one or more functional group(s) present in the active agent in such a way that the modification(s) may be cleaved in vivo to release the parent compound.\n\nProdrugs include compounds wherein a hydroxy, amino or sulfhydryl group in the active agent is bonded to any group, e.g., protecting group, that may be cleaved in vivo to regenerate the free hydroxyl, amino or sulfhydryl group, respectively.\n\nprodrugs include, but are not limited to, active agents whose functional group(s) are protected by one or more protecting groups listed in T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 3 rd edition, John Wiley & Sons, New York, 1999, and Harrison and Harrison et al., Compendium of Synthetic Organic Methods , Vols. 1â8 (John Wiley and Sons, 1971â1996), which are incorporated herein by reference in their entirety.\n\nRepresentative hydroxy protecting groups which are useful in preparing prodrugs include acyl groups (e.g., formyl, acetyl and trifluoroacetyl), alkyl ethers, phosphate ethers, phosphate esters, and the like.\n\nRepresentative amino protecting groups that are useful in preparing prodrugs include acyl groups (e.g., formyl, acetyl, and trifluoroacetyl), benzyloxycarbonyl (CBZ), tert-butoxycarbonyl (Boc), and the like.\n\nantibiotic and âantibacterialâ are used herein interchangeably to refer to a compound that inhibits the growth of, inhibits the virulence of, or kills bacterial cells.\n\nAntibiotics include, e.g., substances produced by various species of microorganisms (e.g., bacteria, fungi, and actinomycetes), variants thereof, and synthetic antibacterial agents.\n\na complete list of antibiotics is too long to be included herein, and those of skill in the art are aware of the multitude of antibiotics that can be used in the present invention.\n\nSuitable antibiotic agents include, but are not limited to, clindamycin, erythromycin, tetracycline, minocycline, doxycycline, penicillin, ampicillin, carbenicillin, methicillin, cephalosporins, vancomycin, and bacitracin, streptomycin, gentamycin, chloramphenicol, fusidic acid, ciprofloxin and other quinolones, sulfonamides, trimethoprim, dapsone, isoniazid, teicoplanin, avoparcin, synercid, virginiamycin, cefotaxime, ceftriaxone, piperacillin, ticarcillin, cefepime, cefpirome, rifampicin, pyrazinamide, ciprofloxacin, levofloxacin, enrofloxacin, amikacin, netilmycin, imipenem, meropenem, inezolid, pharmaceutically acceptable\n\nthe antibiotic agent is clindamycin, erythromycin, tetracycline, minocycline, doxycycline, pharmaceutically acceptable salts thereof, or prodrugs thereof. More preferably, the antibiotic agent is clindamycin, or a pharmaceutically acceptable salt or a prodrug thereof.\n\nVehicle refers to a composition which has only excipient or components required to carry an active agent, but which itself has no pharmaceutical or therapeutic effect.\n\nfatty alcohol refers to C 14 âC 22 alcohol(s).\n\npH is defined as the value given by a suitable, properly standardized pH meter using an appropriate electrode.\n\na topical delivery composition in a pressurized container comprises: up to 15% w/w of at least one pharmaceutically active compound, or its pharmaceutically acceptable salt or a prodrug thereof; from about 83% to about 97.9% w/w of a quick-breaking foaming agent; and from about 2% to about 7% w/w of an aerosol propellant selected from the group consisting of a hydrocarbon, a chlorofluorocarbon, and a mixture thereof, wherein the composition is a quick-breaking temperature sensitive foam after release from the container.\n\ncompositions of the present invention are present in a pressurized container comprising a homogeneous mixture of: from about 0.1% to about 10% w/w of a pharmaceutically active compound, or its pharmaceutically acceptable salt or a prodrug thereof; from about 83% to about 97.9% w/w of a quick-breaking foaming agent; and from about 2% to about 7% w/w of an aerosol propellant selected from the group consisting of a hydrocarbon, a chlorofluorocarbon, and a mixture thereof.\n\na quick-breaking temperature sensitive foam is formed.\n\nthe maximum amount of propellant used is often determined by its miscibility with other components in the composition to form a mixture, such as a homogeneous mixture.\n\nthe minimal level of propellant used in the composition is often determined by the desired foam characteristics, and its ability to substantially or completely evacuate the container.\n\nthe quick-breaking foaming agent comprises water and a surfactant, or a combination of surfactants, and an optional component(s), such as a C 1 âC 6 alcohol, a C 14 âC 22 alcohol, and combinations thereof.\n\nthe quick-breaking foaming agent can also comprise an emollient, which can also act as a humectant.\n\nSuitable emollients include, but are not limited to, polyols.\n\nPreferred polyols include propylene glycol and glycerol.\n\nthe amount of emollient used in the quick-breaking foaming agent varies from about 0% to about 20% w/w, preferably from about 0% to about 10% w/w, and more preferably from about 2% to about 7.5% w/w.\n\nthe quick-breaking foaming agent comprises a C 1 âC 6 alcohol and water. In a preferred embodiment, the quick-breaking foaming agent comprises a C 1 âC 6 alcohol, a C 14 âC 22 alcohol, water, and a surfactant. In an alternative embodiment, the quick-breaking foaming agent does not contain a C 1 âC 6 alcohol.\n\nthe quick-breaking foaming agent can also comprise a pH adjusting agent.\n\nthe pH adjusting agent is a base. Suitable pH adjusting bases include bicarbonates, carbonates, and hydroxides such as alkali or alkaline earth metal hydroxide as well as transition metal hydroxides.\n\nthe pH adjusting agent is potassium hydroxide.\n\nthe pH adjusting agent can also be an acid, an acid salt, or mixtures thereof.\n\nthe pH adjusting agent can also be a buffer.\n\nSuitable buffers include citrate/citric acid buffers, acetate/acetic acid buffers, phosphate/phosphoric acid buffers, formate/formic acid buffers, propionate/propionic acid buffers, lactate/lactic acid buffers, carbonate/carbonic acid buffers, ammonium/ammonia buffers, and the like.\n\nthe pH adjusting agent is present in an amount sufficient to adjust the pH of the composition to between about pH 4.0 to about 9.0, preferably about pH 4.0 to about 6.5.\n\nthe quick-breaking foaming agent composition comprises a C 1 âC 6 alcohol, more preferably a C 1 âC 4 alcohol, such as methanol, ethanol, propanol e.g., isopropanol, butanol, and a mixture of two or more thereof.\n\na particularly preferred C 1 âC 6 alcohol is ethanol or a mixture of ethanol with and at least one other alcohol.\n\nthe amount of C 1 âC 6 alcohol used in the quick-breaking foaming agent varies from about 0% to about 95% w/w, preferably from about 55% to about 65% w/w, and more preferably from about 58% to about 60% w/w.\n\nthe amount of C 14 âC 22 alcohol in the quick-breaking foaming agent varies from about 0% to about 10% w/w, preferably from about 1% to about 5.0% w/w.\n\nthe quick-breaking foaming agent preferably comprises from about 1% to about 2.5% w/w of the C 14 âC 22 alcohol.\n\nAn especially preferred amount of C 14 âC 22 alcohol in the quick-breaking foaming agent is from about 1.5% to about 2% w/w.\n\na preferred C 14 âC 22 alcohol in the quick-breaking foaming agent is a C 16 âC 20 alcohol.\n\ncetyl alcohol, stearyl alcohol, or a mixture thereof is particularly preferred.\n\na mixture of cetyl alcohol and stearyl alcohol is particularly preferred.\n\nthe ratio of cetyl alcohol to stearyl alcohol can range from about 60:40 to about 80:20, with the ratio of about 70:30 being a preferred mixture ratio.\n\nsurfactants are useful in compositions of the present invention including, for example, ethoxylated non-ionic and ethoxylated ionic surfactants.\n\nSuitable surfactants for use in compositions of the present invention include, but are not limited to, fatty acid ethoxylates, fatty alcohol ethoxylates, polysorbates, glycerol ester ethoxylates, and block copolymers such as poloxamers. Examples of these include Polysorbate 20, Polysorbate 60, Polysorbate 80, Laureth-4, Laureth-23, POE(15) glycerol monolaurate, and the like.\n\nthe surfactant is Polysorbate 60, Laureth-4, POE(15) glycerol monolaurate, or mixtures thereof.\n\nthe amount of surfactant present in the quick-breaking foaming agent generally ranges from about 0% to about 10% w/w, preferably from about 0.1% to about 10% w/w, more preferably from about 0.1% to about 6% w/w, with from about 0.5% to about 5% w/w and from about 0.3% to about 0.5% w/w being especially preferred amounts.\n\nWater, and optionally, a pH adjusting agent generally comprises the remaining portion of the quick-breaking foaming agent.\n\nthe amount of water present in the quick-breaking foaming agent ranges from about 10% to about 95% w/w, preferably from about 10% to about 90% w/w, more preferably from about 20% to about 90% w/w, with from about 30% to about 40% w/w, or alternatively from about 80% to about 95% w/w, being especially preferred.\n\nthe quick-breaking temperature sensitive foam is formulated such that the foam breaking temperature is at or near skin temperature.\n\nthe foam breaking temperature can be modulated by changing the ratio of various components of the quick-breaking foaming agent, e.g., the C 1 âC 6 alcohol to water ratio.\n\nthe foam breaking temperature can be adjusted to be from about 30Â° C. to about 36Â° C., such as 30Â° C., 31Â° C., 32Â° C., 33Â° C., 34Â° C., 35Â° C., and 36Â° C.\n\na particularly preferred foam breaking temperature for clindamycin foam is 35Â° C.\n\nthe pressurized container is a one-piece aluminum container in which the inner surface is lined with a chemically inert lining.\n\na preferred inner surface lining is polyamide-imide (PAM) lacquer, supplied by HOBA Lacke und Weg GmbH.\n\nPAM polyamide-imide\n\nthe container is fitted with an upright or inverted valve and a conventional foam spout actuator.\n\nthe present invention provides various aspects related to such compositions, including: methods for modulating a foam characteristic; methods for improving the shelf-life of a pharmaceutically active compound or its pharmaceutically acceptable salt or a prodrug thereof; methods for percutaneous treatment of various diseases, infections, and illnesses; and methods for evaluating foam characteristics.\n\nthe at least one pharmaceutically active compound is an antibacterial agent.\n\nSuitable antibacterial agents include, but are not limited to, clindamycin, erythromycin, tetracycline, minocycline, doxycycline, penicillin, ampicillin, carbenicillin, methicillin, cephalosporins, vancomycin, and bacitracin, streptomycin, gentamycin, chloramphenicol, fusidic acid, ciprofloxin and other quinolones, sulfonamides, trimethoprim, dapsone, isoniazid, teicoplanin, avoparcin, synercid, virginiamycin, cefotaxime, ceftriaxone, piperacillin, ticarcillin, cefepime, cefpirome, rifampicin, pyrazinamide, ciprofloxacin, levofloxacin, enrofloxacin, amikacin, netilmycin,\n\nClindamycin is an antibiotic also known as methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo- â -D-galacto-octo-pyranoside or methyl 7-chloro-6,7,8-trideoxy-6-[[(1-methyl-4-propyl-2-pyrrolidinyl)carbonyl]amino]-1-thio-L-threo- â -D-galacto-octo-pyranoside.\n\nthe term âclindamycinâ alone includes free-base clindamycin as well as the pharmaceutically acceptable salts and esters thereof.\n\nExamples of pharmaceutically acceptable salts and esters of clindamycin include, but are not limited to, clindamycin hydrochloride, clindamycin phosphate, clindamycin palmitate, and clindamycin palmitate hydrochloride. It is preferred to use a clindamycin salt or ester in the compositions of the present invention, with clindamycin phosphate being especially preferred.\n\nSuitable concentration ranges of the at least one pharmaceutically active compound include, for example, from about 0.001% to about 50% w/w, preferably from about 0.01% to about 20% w/w, such as up to 15% w/w, and more preferably from about 0.1% to about 2% w/w. About 1% w/w is especially preferred.\n\nclindamycin such as clindamycin phosphate\n\nclindamycin phosphate is a water soluble pharmaceutical agent.\n\nthe melting point of the composition needed to be within the temperature ranges already set forth (e.g., at or near skin temperature). In certain instances, the melting point needed to be adjusted and raised, which was difficult due to the water solubility of clindamycin and the high concentrations of clindamycin used. These difficulties were overcome in part by adjusting the C 1 âC 6 alcohol to water ratios, such as the ethanol to water ratio.\n\nHigh concentrations of active compounds can also impact foam structure and foam quality, as well as cause unwanted crystallization.\n\nWater-soluble active compounds can, in effect, remove water from the system, virtually changing the ratio of water to C 1 âC 6 alcohol, and therefore the foam characteristics, including the melting point. This may require intervention to achieve an acceptable foam quality.\n\nthe C 1 âC 6 alcohol may not be a good solvent for water-soluble active compounds, allowing crystallization at lower temperatures. Simply increasing the water content to prevent crystallization will alter the foam characteristics and will change the solubility of the fatty alcohols, possibly causing them to precipitate. Crystallization can lead to loss of pharmaceutically active compounds and/or blockage of the aerosol valve.\n\nAddition of a buffer is often used to improve the stability of an active compound, and, in the case of aerosol containers, to reduce corrosion of the metal.\n\nthe buffer can make the formulation less stable rather than more stable.\n\na pH adjustment rather than full buffering may be more effective. This is shown in FIG. 3 , where higher levels of buffer cause more degradation rather than less degradation.\n\nclindamycin phosphate is the active agent and the quick-breaking foaming agent comprises a mixture of cetyl alcohol and stearyl alcohol, which are dissolved in a water/ethanol solution.\n\nthis composition is packaged in a polyamide-imide-lined aluminum can and pressurized with a propane/butane mixture as the propellant. Under the packaged pressure, the hydrocarbon propellant liquefies and becomes miscible with the water/ethanol solution. This liquefied hydrocarbon/water/ethanol solution allows increased solubility of the cetyl and stearyl alcohols compared to water/ethanol solutions alone. At temperatures above 11Â° C., the contents of the can under pressure remain as a clear homogeneous solution.\n\nthe foam structure i.e., characteristic, which is formed when the composition is released from the can is controlled by the solubility of the fatty alcohols (e.g., a mixture of cetyl alcohol and stearyl alcohol) in the aqueous/ethanolic solution.\n\nthe propellant expands and vaporizes, allowing the fatty alcohols (e.g., a mixture of cetyl alcohol and stearyl alcohol) to form a stable foam structure.\n\nthe ratios and choice of these components affect the physical characteristics of the foam.\n\nthe water, ethanol, and propellant levels are selected to provide the minimum solubility of the fatty alcohols in the can.\n\nthe present inventors have discovered that a change in the water:ethanol ratio alters foam characteristics. For example, an increase in the water:ethanol ratio leads to a decrease in solubility of the fatty alcohols and an ensuing solidification of the foam structure. Conversely, a decrease in the water:ethanol ratio leads to an increase in solubility of the fatty alcohols and results in the formation of a more fluid foam.\n\nPolysorbate is used as the preferred surfactant, with Polysorbate 60 being an especially preferred surfactant. Without being bound by any theory, in addition to its role in foam formation, it is believed that Polysorbate 60 enhances cetyl alcohol and/or stearyl alcohol solubility.\n\nthe topical delivery composition of clindamycin phosphate is typically accomplished by first dissolving the components into either water or ethanol. Due to their limited solubility in water, cetyl alcohol and stearyl alcohol are dissolved in the ethanolic phase. Polysorbate 60 and propylene glycol (i.e., an emollient which also can act as a humectant) are soluble in both ethanol and water, but for convenience are dissolved in the ethanolic phase. Clindamycin phosphate and potassium hydroxide (i.e., a pH adjusting agent) are dissolved in water. The aqueous and ethanolic phases are then added at the appropriate ratio into the individual cans during the filling operation.\n\naqueous and ethanolic phases are then added at the appropriate ratio into the individual cans during the filling operation.\n\nvalves are fitted to the cans and crimped into place. A metered amount of propellant is then injected through the valve to complete the formulation.\n\nAnother means of filling the cans involves a single-liquid-phase fill, in which the composition is kept warm to ensure homogeneity, followed by crimping and propellant injection.\n\nYet another means involves formulating the entire composition, including the propellant, in bulk, under pressure, and then injecting the formulation into the crimped aerosol can.\n\na representative topical delivery clindamycin phosphate composition of the present invention Component Amount (% w/w) Clindamycin phosphate, USP (calculated as 1.25 clindamycin) Dehydrated Alcohol (Ethanol), USP 58.21 Cetyl Alcohol, NF 1.16 Stearyl Alcohol, NF 0.53 Polysorbate 60, NF 0.42 Propylene Glycol, USP 2.11 Purified Water, USP 36.21 Potassium Hydroxide, USP, 10% w/w soln.\n\nthe amount of clindamycin phosphate is based on its purity (typically 800 mg/g calculated as clindamycin), and is adjusted to provide 1.00% calculated as clindamycin in the final composition, as shown in Table 1. Thus, the exact amount of clindamycin phosphate can vary depending on its purity.\n\nthe amount of propellant added to the topical delivery clindamycin phosphate composition is about 2.8 g of propane/butane propellant for each about 50 g of the above mixture.\n\nthe hydrocarbon or mixtures thereof helps to dissolve the cetyl alcohol and stearyl alcohol in the aqueous/ethanolic system to produce a clear, one-phase (i.e., homogeneous) system in the container.\n\nthe range of propellant concentration is from about 2% to about 7% w/w relative to the total amount of composition, preferably from about 3% to about 6% w/w, and more preferably in the range of from about 4.6% to about 5.4% w/w.\n\nchlorofluorocarbons can also be used as propellants\n\nthe preferred propellants are hydrocarbons, in particular, propane, butane, or a mixture thereof.\n\nsuitable propellants include dimethyl ether and hydrofluorocarbons such as 134a and 227.\n\nAn especially preferred propellant is a mixture of propane and butane.\n\nTable 2 summarizes some of the functions of each component in the clindamycin phosphate compositions of the present invention.\n\nthe pressurized container is fitted with a dip tube; hence, the composition is dispensed by holding the can upright and depressing the actuator button.\n\nthe dispensed foam is thermolabile, i.e., a quick-breaking temperature sensitive foam.\n\nthe foam structure collapses at, i.e., the foam breaking temperature is, approximately skin temperature, preferably between about 30Â° C. to about 36Â° C., with the foam breaking temperature of about 35Â° C. being especially preferred.\n\nthe foam breaking temperature is, approximately skin temperature, preferably between about 30Â° C. to about 36Â° C., with the foam breaking temperature of about 35Â° C. being especially preferred.\n\nthe foam breaking temperature is, approximately skin temperature, preferably between about 30Â° C. to about 36Â° C., with the foam breaking temperature of about 35Â° C. being especially preferred.\n\nthe clindamycin phosphate foam is generally dispensed onto a convenient surface prior to topical application.\n\nthe thermolabile nature of the clindamycin phosphate foam requires the dispensing of the composition onto a saucer, the cap of the can, or other cool surface so as to maintain the integrity of the foam structure.\n\nthe clindamycin phosphate foam can then be applied with a hand or an applicator.\n\nthermolabile qualities of the dispensed foam vehicle as a function of temperature are shown in FIG. 1 , which shows a critical temperature, i.e., foam breaking temperature, of about 35Â° C. Below this temperature, the foam remains quite stable and retains structural integrity for over 5 minutes. Above 35Â° C., the cetyl and stearyl alcohol redissolve and the foam breaks down.\n\nfoam breaking temperature i.e., foam breaking temperature\n\nthe quality of the clindamycin phosphate foam is also affected by the ambient temperature. For example, containers stored at higher temperatures (i.e., between 28Â° C. and 34Â° C.) dispense a softer clindamycin phosphate foam than those dispensed at lower temperatures (i.e., below 25Â° C.).\n\na general description of clindamycin phosphate foam quality as a function of container temperature is shown in Table 3 below.\n\na preferred clindamycin phosphate foam dispensing temperature is between about 23Â° C. to about 27Â° C., such as 25Â° C. or below.\n\nthe temperature effects on foam formation are reversible.\n\ncooling a warmed container that dispenses a soft clindamycin phosphate foam to below 25Â° C. will dispense an acceptable crisp, dry foam.\n\nthe preferred propellant for use in the clindamycin phosphate foam compositions of the present invention comprises a propane and butane mixture.\n\na particularly preferred propellant comprises a mixture of propane, n-butane, and isobutane.\n\na propellant composition comprising about 55% propane, about 30% n-butane, and about 15% isobutane is especially preferred.\n\nthe propellant in the solution evaporates or vaporizes and creates the bubbles of the foam structure. Some of this vaporized propellant is quickly released and dispersed to the atmosphere while the remainder is trapped within the foam structure.\n\nAnother aspect of the present invention provides a method for modulating a foam characteristic of a quick-breaking temperature sensitive foam composition by changing the C 1 âC 6 alcohol to water ratio in the quick-breaking foaming agent.\n\nfoam characteristics can be modified, including, but not limited to, clarity, density, viscosity, foam bubble size, foam expansion rate, foam flow rate, and/or foam breaking temperature.\n\nthe C 1 âC 6 alcohol to water ratio ranges from about 1.5:1 to about 1.8:1, preferably from about 1.55:1 to about 1.75:1, and more preferably from about 1.6:1 to about 1.7:1. In another embodiment, the C 1 âC 6 alcohol to water ratio is less than about 1:7. In yet another embodiment, the C 1 âC 6 alcohol to water ratio ranges from about 1:7 to about 1:16, and is preferably about 1:7 or about 1:16.\n\nthe C 1 âC 6 alcohol to water ratio in the quick-breaking foaming agent is modified to achieve a desired foam breaking temperature.\n\nTable 4 shows the effect of the ethanol to water ratio on the melting point (i.e., foam breaking temperature) of clindamycin phosphate foam. As shown in Table 4, a foam breaking temperature of 35Â° C. is achieved by adjusting the ratio of ethanol to water to 1.60:1. This formulation was used in determining the thermolabile quality as shown in FIG. 1 .\n\nClindamycin phosphate foam compositions of the present invention are useful in treating various bacteria-mediated diseases or illnesses via topical application, e.g., in treating acne vulgaris and bacterial vaginosis.\n\nother antibacterial agents or their corresponding prodrugs can be used instead of clindamycin to treat other bacteria-mediated diseases or illnesses.\n\nSuitable additional antibacterial agents include, but are not limited to, erythromycin, tetracycline, minocycline, doxycycline, pharmaceutically acceptable salts thereof, and prodrugs thereof.\n\nantifungal agents such as ketoconazole can be used to treat fungal infections such as athlete's foot and the like.\n\none or more components of the composition e.g., the quick-breaking foaming agent and/or the propellant\n\na desired foam characteristic e.g., smoothness of the f"
    }
}